Market Research Logo

Chronic Obstructive Pulmonary Disease - Pipeline Review, H1 2017

Chronic Obstructive Pulmonary Disease - Pipeline Review, H1 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Chronic Obstructive Pulmonary Disease - Pipeline Review, H1 2017, provides an overview of the Chronic Obstructive Pulmonary Disease (Respiratory) pipeline landscape.

Chronic obstructive pulmonary disease (COPD) is a group of lung diseases. It is characterized by inability to completely breathe out air from the lungs leading to shortness of breath. The airflow to the lungs is further blocked. Other symptoms include cough, fatigue and chest pain. The disease tends to worsen over the time hence increasing the complications. The risk factors involved in causing COPD include smoking as the primary reason. Exposure to chemicals and air pollution also contribute in the development of COPD.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Chronic Obstructive Pulmonary Disease - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Chronic Obstructive Pulmonary Disease (Respiratory), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Chronic Obstructive Pulmonary Disease (Respiratory) pipeline guide also reviews of key players involved in therapeutic development for Chronic Obstructive Pulmonary Disease (COPD) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 5, 1, 14, 38, 23, 85, 25 and 1 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 9 and 1 molecules, respectively.

Chronic Obstructive Pulmonary Disease (Respiratory) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Chronic Obstructive Pulmonary Disease (Respiratory).
  • The pipeline guide reviews pipeline therapeutics for Chronic Obstructive Pulmonary Disease (Respiratory) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Chronic Obstructive Pulmonary Disease (Respiratory) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Chronic Obstructive Pulmonary Disease (Respiratory) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Chronic Obstructive Pulmonary Disease (Respiratory)
Reasons to buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Chronic Obstructive Pulmonary Disease (Respiratory).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Chronic Obstructive Pulmonary Disease (Respiratory) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.


Introduction
Chronic Obstructive Pulmonary Disease (COPD) - Overview 8
Chronic Obstructive Pulmonary Disease (COPD) - Therapeutics Development 9
Chronic Obstructive Pulmonary Disease (COPD) - Therapeutics Assessment 32
Chronic Obstructive Pulmonary Disease (COPD) - Companies Involved in Therapeutics Development 48
Chronic Obstructive Pulmonary Disease (COPD) - Drug Profiles 97
Chronic Obstructive Pulmonary Disease (COPD) - Dormant Projects 416
Chronic Obstructive Pulmonary Disease (COPD) - Discontinued Products 430
Chronic Obstructive Pulmonary Disease (COPD) - Product Development Milestones 434
Appendix 445
List of Tables
Number of Products under Development for Chronic Obstructive Pulmonary Disease (COPD), H1 2017
Number of Products under Development by Companies, H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..2), H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..3), H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..4), H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..5), H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..6), H1 2017
Number of Products under Development by Universities/Institutes, H1 2017
Products under Development by Companies, H1 2017
Products under Development by Companies, H1 2017 (Contd..1), H1 2017
Products under Development by Companies, H1 2017 (Contd..2), H1 2017
Products under Development by Companies, H1 2017 (Contd..3), H1 2017
Products under Development by Companies, H1 2017 (Contd..4), H1 2017
Products under Development by Companies, H1 2017 (Contd..5), H1 2017
Products under Development by Companies, H1 2017 (Contd..6), H1 2017
Products under Development by Companies, H1 2017 (Contd..7), H1 2017
Products under Development by Companies, H1 2017 (Contd..8), H1 2017
Products under Development by Companies, H1 2017 (Contd..9), H1 2017
Products under Development by Companies, H1 2017 (Contd..10), H1 2017
Products under Development by Universities/Institutes, H1 2017
Number of Products by Stage and Target, H1 2017
Number of Products by Stage and Target, H1 2017 (Contd..1), H1 2017
Number of Products by Stage and Target, H1 2017 (Contd..2), H1 2017
Number of Products by Stage and Target, H1 2017 (Contd..3), H1 2017
Number of Products by Stage and Target, H1 2017 (Contd..4), H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..1), H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..2), H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..3), H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..4), H1 2017
Number of Products by Stage and Route of Administration, H1 2017
Number of Products by Stage and Molecule Type, H1 2017
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Abeona Therapeutics Inc, H1 2017
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Achillion Pharmaceuticals Inc, H1 2017
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Adamis Pharmaceuticals Corp, H1 2017
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Advanced Inhalation Therapies (AIT) Ltd, H1 2017
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Advinus Therapeutics Ltd, H1 2017
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by AlgiPharma AS, H1 2017
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Allinky Biopharma, H1 2017
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Alteogen Inc, H1 2017
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Amakem NV, H1 2017
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Angiocrine Bioscience Inc, H1 2017
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Angion Biomedica Corp, H1 2017
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by apceth Biopharma GmbH, H1 2017
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Apellis Pharmaceuticals Inc, H1 2017
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Aridis Pharmaceuticals LLC, H1 2017
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Astellas Pharma Inc, H1 2017
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by AstraZeneca Plc, H1 2017
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Asubio Pharma Co Ltd, H1 2017
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Axikin Pharmaceuticals Inc, H1 2017
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Bayer AG, H1 2017
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Beech Tree Labs Inc, H1 2017
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Bioneer Corp, H1 2017
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Boehringer Ingelheim GmbH, H1 2017
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by C4X Discovery Holdings PLC, H1 2017
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Carolus Therapeutics Inc, H1 2017
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Cellular Biomedicine Group Inc, H1 2017
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Celon Pharma SA, H1 2017
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Chiesi Farmaceutici SpA, H1 2017
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Circassia Pharmaceuticals Plc, H1 2017
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by CSL Ltd, H1 2017
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Cytokinetics Inc, H1 2017
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Daiichi Sankyo Company Ltd, H1 2017
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Diffusion Pharmaceuticals Inc, H1 2017
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Domainex Ltd, H1 2017
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Enterprise Therapeutics Ltd, H1 2017
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Errant Gene Therapeutics LLC, H1 2017
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by F. Hoffmann-La Roche Ltd, H1 2017
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Foresee Pharmaceuticals LLC, H1 2017
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Galapagos NV, H1 2017
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Gilead Sciences Inc, H1 2017
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by GlaxoSmithKline Plc, H1 2017
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Glenmark Pharmaceuticals Ltd, H1 2017
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Grifols SA, H1 2017
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Hanmi Pharmaceuticals Co Ltd, H1 2017
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by iCeutica Inc, H1 2017
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by InMed Pharmaceuticals Inc, H1 2017
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Innate Pharma SA, H1 2017
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Insmed Inc, H1 2017
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Intech Biopharm Ltd, H1 2017
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Invion Ltd, H1 2017
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Jiangsu Hansoh Pharmaceutical Group Co Ltd, H1 2017
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Johnson & Johnson, H1 2017
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by KaloBios Pharmaceuticals Inc, H1 2017
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Kissei Pharmaceutical Co Ltd, H1 2017
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Kyowa Hakko Kirin Co Ltd, H1 2017
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Medestea Research & Production SpA, H1 2017
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by MedImmune LLC, H1 2017
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Mereo Biopharma Group Plc, H1 2017
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Meridigen Biotech Co Ltd, H1 2017
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Microbion Corp, H1 2017
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Novartis AG, H1 2017
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Odan Laboratories Ltd, H1 2017
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by OPKO Health Inc, H1 2017
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Orchid Pharma Ltd, H1 2017
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Orion Oyj, H1 2017
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Pfizer Inc, H1 2017
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Pharmaxis Ltd, H1 2017
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Promedior Inc, H1 2017
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by ProMetic Life Sciences Inc, H1 2017
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Proteostasis Therapeutics Inc, H1 2017
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Pulmagen Therapeutics LLP, H1 2017
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Pulmatrix Inc, H1 2017
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Qu Biologics Inc, H1 2017
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Quark Pharmaceuticals Inc, H1 2017
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Re-Pharm Ltd, H1 2017
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Regeneron Pharmaceuticals Inc, H1 2017
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Respira Therapeutics Inc, H1 2017
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Respiratorius AB, H1 2017
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by rEVO Biologics Inc, H1 2017
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Rhizen Pharmaceuticals SA, H1 2017
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by SATT North SAS, H1 2017
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Seoul Pharma Co Ltd, H1 2017
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by sterna biologicals Gmbh & Co KG, H1 2017
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Sun Pharma Advanced Research Company Ltd, H1 2017
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Sunovion Pharmaceuticals Inc, H1 2017
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Synedgen Inc, H1 2017
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Syntrix Biosystems Inc, H1 2017
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Takeda Pharmaceutical Company Ltd, H1 2017
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Teva Pharmaceutical Industries Ltd, H1 2017
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Therabron Therapeutics Inc, H1 2017
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Theravance Biopharma Inc, H1 2017
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Torrent Pharmaceuticals Ltd, H1 2017
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Unizyme Laboratories A/S, H1 2017
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Vectura Group Plc, H1 2017
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Verona Pharma Plc, H1 2017
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Vertex Pharmaceuticals Inc, H1 2017
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Yuhan Corp, H1 2017
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Yungjin Pharm Co Ltd, H1 2017
Chronic Obstructive Pulmonary Disease (COPD) - Dormant Projects, H1 2017
Chronic Obstructive Pulmonary Disease (COPD) - Dormant Projects, H1 2017 (Contd..1), H1 2017
Chronic Obstructive Pulmonary Disease (COPD) - Dormant Projects, H1 2017 (Contd..2), H1 2017
Chronic Obstructive Pulmonary Disease (COPD) - Dormant Projects, H1 2017 (Contd..3), H1 2017
Chronic Obstructive Pulmonary Disease (COPD) - Dormant Projects, H1 2017 (Contd..4), H1 2017
Chronic Obstructive Pulmonary Disease (COPD) - Dormant Projects, H1 2017 (Contd..5), H1 2017
Chronic Obstructive Pulmonary Disease (COPD) - Dormant Projects, H1 2017 (Contd..6), H1 2017
Chronic Obstructive Pulmonary Disease (COPD) - Dormant Projects, H1 2017 (Contd..7), H1 2017
Chronic Obstructive Pulmonary Disease (COPD) - Dormant Projects, H1 2017 (Contd..8), H1 2017
Chronic Obstructive Pulmonary Disease (COPD) - Dormant Projects, H1 2017 (Contd..9), H1 2017
Chronic Obstructive Pulmonary Disease (COPD) - Dormant Projects, H1 2017 (Contd..10), H1 2017
Chronic Obstructive Pulmonary Disease (COPD) - Dormant Projects, H1 2017 (Contd..11), H1 2017
Chronic Obstructive Pulmonary Disease (COPD) - Dormant Projects, H1 2017 (Contd..12), H1 2017
Chronic Obstructive Pulmonary Disease (COPD) - Dormant Projects, H1 2017 (Contd..13), H1 2017
Chronic Obstructive Pulmonary Disease (COPD) - Discontinued Products, H1 2017
Chronic Obstructive Pulmonary Disease (COPD) - Discontinued Products, H1 2017 (Contd..1), H1 2017
Chronic Obstructive Pulmonary Disease (COPD) - Discontinued Products, H1 2017 (Contd..2), H1 2017
Chronic Obstructive Pulmonary Disease (COPD) - Discontinued Products, H1 2017 (Contd..3), H1 2017
List of Figures
Number of Products under Development for Chronic Obstructive Pulmonary Disease (COPD), H1 2017
Number of Products under Development by Companies, H1 2017
Number of Products under Development by Universities/Institutes, H1 2017
Number of Products by Top 10 Targets, H1 2017
Number of Products by Stage and Top 10 Targets, H1 2017
Number of Products by Top 10 Mechanism of Actions, H1 2017
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017
Number of Products by Top 10 Routes of Administration, H1 2017
Number of Products by Stage and Top 10 Routes of Administration, H1 2017
Number of Products by Top 10 Molecule Types, H1 2017
Number of Products by Stage and Top 10 Molecule Types, H1 2017

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report